{ "ticker": "MET", "cik": "0001099219", "company": "MetLife, Inc.", "business_type": "insurer", "schema_template": "insurer: premiums, policy fees, net investment income, investment and derivative gains (losses), benefits, interest credited, expenses, net income available to common shareholders, diluted EPS; investments, separate accounts, policyholder liabilities, debt, equity and AOCI; operating, investing and financing cash flows; plus the company's adjusted earnings measure", "reporting_currency": "USD", "converted_to_usd": false, "units": "actual US dollars (not millions); per-share figures in dollars per common share; share counts in actual shares", "units_notes_seen": { "FY2025 10-K consolidated statements of operations": "(In millions, except per share data)", "FY2025 10-K consolidated statements of comprehensive income (loss)": "(In millions)", "FY2025 10-K consolidated balance sheets": "(In millions, except share and per share data)", "FY2025 10-K consolidated statements of equity": "(In millions, except per share data)", "FY2025 10-K consolidated statements of cash flows": "(In millions)", "FY2025 10-K Note 23 earnings per common share": "(In millions, except per share data)", "FY2025 10-K MD&A adjusted earnings available to common shareholders by segment": "(In millions)", "Q3 2026 10-Q interim condensed consolidated balance sheets": "(In millions, except share and per share data)", "Q3 2026 10-Q interim condensed consolidated statements of operations and comprehensive income (loss)": "(In millions, except per share data)", "Q3 2026 10-Q interim condensed consolidated statements of equity": "(In millions, except per share data)", "Q3 2026 10-Q interim condensed consolidated statements of cash flows": "(In millions)", "Q3 2026 10-Q Note 17 earnings per common share": "(In millions, except per share data)", "Q3 2026 10-Q MD&A reconciliations to adjusted earnings available to common shareholders": "(In millions)", "Q3 2026 earnings release (Exhibit 99.1) adjusted earnings per share and book value tables": "(In millions, except per share data)" }, "adjustments": { "splits_applied": [], "adr_ratio": null, "fx": "none - MetLife reports in US dollars" }, "annual": [ { "fiscal_year": 2025, "label": "FY2025", "period_start": "2025-01-01", "period_end": "2025-12-31", "period_type": "fiscal year", "source_accession": "0001099219-26-000013", "income_statement": { "premiums": 49779000000, "universal_life_and_investment_type_product_policy_fees": 5003000000, "net_investment_income": 22559000000, "other_revenues": 2827000000, "net_investment_gains_losses": -1145000000, "net_derivative_gains_losses": -1939000000, "total_revenues": 77084000000, "policyholder_benefits_and_claims": 49718000000, "policyholder_liability_remeasurement_gains_losses": -150000000, "market_risk_benefit_remeasurement_gains_losses": -508000000, "interest_credited_to_policyholder_account_balances": 8950000000, "policyholder_dividends": 553000000, "other_expenses": 13860000000, "total_expenses": 72423000000, "income_before_provision_for_income_tax": 4661000000, "provision_for_income_tax": 1258000000, "net_income": 3403000000, "net_income_attributable_to_noncontrolling_interests": 24000000, "net_income_attributable_to_metlife_inc": 3379000000, "preferred_stock_dividends": 194000000, "preferred_stock_redemption_premium": 12000000, "net_income_available_to_common_shareholders": 3173000000, "basic_eps": 4.74, "diluted_eps": 4.71, "weighted_average_basic_shares": 668900000, "weighted_average_diluted_shares": 673300000, "dividends_declared_per_common_share": 2.248 }, "comprehensive_income": { "comprehensive_income": 7581000000, "comprehensive_income_attributable_to_metlife_inc": 7555000000 }, "cash_flow": { "operating_cash_flow": 17092000000, "investing_cash_flow": -15607000000, "financing_cash_flow": 163000000, "treasury_stock_acquired_share_repurchases": -2883000000, "preferred_dividends_paid": -194000000, "common_dividends_paid": -1509000000, "change_in_cash_and_cash_equivalents": 1964000000 }, "balance_sheet": { "total_investments": 472178000000, "cash_and_cash_equivalents": 22032000000, "separate_account_assets": 151933000000, "total_assets": 745166000000, "future_policy_benefits": 208855000000, "policyholder_account_balances": 236857000000, "short_term_debt": 355000000, "long_term_debt": 14467000000, "collateral_financing_arrangement": 352000000, "subordinated_debt_securities": 4155000000, "total_liabilities": 716245000000, "redeemable_noncontrolling_interests": 241000000, "accumulated_other_comprehensive_income_loss": -18084000000, "total_metlife_inc_stockholders_equity": 28398000000, "noncontrolling_interests": 282000000, "total_equity": 28680000000, "common_shares_outstanding": 655333773 }, "non_gaap_and_other_measures": { "adjusted_earnings_available_to_common_shareholders": 5943000000, "adjusted_earnings_available_to_common_by_segment": { "group_benefits": 1692000000, "ris": 1671000000, "asia": 1702000000, "latin_america": 798000000, "emea": 367000000, "mim": 200000000, "corporate_and_other": -487000000 }, "sources": "MD&A of accession 0001099219-26-000013." } }, { "fiscal_year": 2024, "label": "FY2024", "period_start": "2024-01-01", "period_end": "2024-12-31", "period_type": "fiscal year", "source_accession": "0001099219-26-000013", "income_statement": { "preferred_stock_redemption_premium": 0, "premiums": 44945000000, "universal_life_and_investment_type_product_policy_fees": 4974000000, "net_investment_income": 21273000000, "other_revenues": 2601000000, "net_investment_gains_losses": -1184000000, "net_derivative_gains_losses": -1623000000, "total_revenues": 70986000000, "policyholder_benefits_and_claims": 44728000000, "policyholder_liability_remeasurement_gains_losses": -206000000, "market_risk_benefit_remeasurement_gains_losses": -1109000000, "interest_credited_to_policyholder_account_balances": 8339000000, "policyholder_dividends": 595000000, "other_expenses": 13017000000, "total_expenses": 65364000000, "income_before_provision_for_income_tax": 5622000000, "provision_for_income_tax": 1178000000, "net_income": 4444000000, "net_income_attributable_to_noncontrolling_interests": 18000000, "net_income_attributable_to_metlife_inc": 4426000000, "preferred_stock_dividends": 200000000, "net_income_available_to_common_shareholders": 4226000000, "basic_eps": 5.98, "diluted_eps": 5.94, "weighted_average_basic_shares": 706400000, "weighted_average_diluted_shares": 711100000, "dividends_declared_per_common_share": 2.155 }, "comprehensive_income": { "comprehensive_income": 2504000000, "comprehensive_income_attributable_to_metlife_inc": 2482000000 }, "cash_flow": { "operating_cash_flow": 14598000000, "investing_cash_flow": -11493000000, "financing_cash_flow": -3131000000, "treasury_stock_acquired_share_repurchases": -3207000000, "preferred_dividends_paid": -200000000, "common_dividends_paid": -1527000000, "change_in_cash_and_cash_equivalents": -571000000 }, "balance_sheet": { "total_investments": 441364000000, "cash_and_cash_equivalents": 20068000000, "separate_account_assets": 139504000000, "total_assets": 677457000000, "future_policy_benefits": 193646000000, "policyholder_account_balances": 221445000000, "short_term_debt": 465000000, "long_term_debt": 15086000000, "collateral_financing_arrangement": 476000000, "subordinated_debt_securities": 3164000000, "total_liabilities": 649754000000, "redeemable_noncontrolling_interests": 0, "accumulated_other_comprehensive_income_loss": -21186000000, "total_metlife_inc_stockholders_equity": 27445000000, "noncontrolling_interests": 258000000, "total_equity": 27703000000, "common_shares_outstanding": 689211065 }, "non_gaap_and_other_measures": { "adjusted_earnings_available_to_common_shareholders": 5796000000, "adjusted_earnings_available_to_common_by_segment": { "group_benefits": 1606000000, "ris": 1667000000, "asia": 1621000000, "latin_america": 881000000, "emea": 283000000, "mim": 55000000, "corporate_and_other": -317000000 }, "sources": "MD&A of accession 0001099219-26-000013." } }, { "fiscal_year": 2023, "label": "FY2023", "period_start": "2023-01-01", "period_end": "2023-12-31", "period_type": "fiscal year", "source_accession": "0001099219-26-000013", "income_statement": { "premiums": 44283000000, "universal_life_and_investment_type_product_policy_fees": 5152000000, "net_investment_income": 19908000000, "other_revenues": 2526000000, "net_investment_gains_losses": -2824000000, "net_derivative_gains_losses": -2140000000, "total_revenues": 66905000000, "policyholder_benefits_and_claims": 44590000000, "policyholder_liability_remeasurement_gains_losses": -45000000, "market_risk_benefit_remeasurement_gains_losses": -994000000, "interest_credited_to_policyholder_account_balances": 7860000000, "policyholder_dividends": 622000000, "other_expenses": 12710000000, "total_expenses": 64743000000, "income_before_provision_for_income_tax": 2162000000, "provision_for_income_tax": 560000000, "net_income": 1602000000, "net_income_attributable_to_noncontrolling_interests": 24000000, "net_income_attributable_to_metlife_inc": 1578000000, "preferred_stock_dividends": 198000000, "preferred_stock_redemption_premium": 0, "net_income_available_to_common_shareholders": 1380000000, "basic_eps": 1.82, "diluted_eps": 1.81, "weighted_average_basic_shares": 757700000, "weighted_average_diluted_shares": 762300000, "dividends_declared_per_common_share": 2.06 }, "comprehensive_income": { "comprehensive_income": 4963000000, "comprehensive_income_attributable_to_metlife_inc": 4957000000 }, "cash_flow": { "operating_cash_flow": 13721000000, "investing_cash_flow": -10246000000, "financing_cash_flow": -2940000000, "treasury_stock_acquired_share_repurchases": -3103000000, "preferred_dividends_paid": -198000000, "common_dividends_paid": -1566000000, "change_in_cash_and_cash_equivalents": 444000000 }, "non_gaap_and_other_measures": { "adjusted_earnings_available_to_common_shareholders": 5525000000, "adjusted_earnings_available_to_common_by_segment": { "group_benefits": 1655000000, "ris": 1708000000, "asia": 1282000000, "latin_america": 840000000, "emea": 265000000, "mim": 70000000, "corporate_and_other": -295000000 }, "sources": "MD&A of accession 0001099219-26-000013." } } ], "quarterly": [ { "fiscal_year": 2026, "fiscal_quarter": 3, "label": "Q3 FY2026", "period_start": "2026-07-01", "period_end": "2026-09-30", "period_type": "three months", "source_accession": "0001099219-26-000062", "income_statement": { "premiums": 11818000000, "universal_life_and_investment_type_product_policy_fees": 1385000000, "net_investment_income": 6198000000, "other_revenues": 853000000, "net_investment_gains_losses": -430000000, "net_derivative_gains_losses": 698000000, "total_revenues": 20522000000, "policyholder_benefits_and_claims": 11474000000, "policyholder_liability_remeasurement_gains_losses": 138000000, "market_risk_benefit_remeasurement_gains_losses": -320000000, "interest_credited_to_policyholder_account_balances": 2201000000, "policyholder_dividends": 136000000, "other_expenses": 3893000000, "total_expenses": 17522000000, "income_before_provision_for_income_tax": 3000000000, "provision_for_income_tax": 588000000, "net_income": 2412000000, "net_income_attributable_to_noncontrolling_interests": 15000000, "net_income_attributable_to_metlife_inc": 2397000000, "preferred_stock_dividends": 46000000, "preferred_stock_redemption_premium": 0, "net_income_available_to_common_shareholders": 2351000000, "basic_eps": 3.7, "diluted_eps": 3.67, "weighted_average_basic_shares": 635000000, "weighted_average_diluted_shares": 639900000, "dividends_declared_per_common_share": 0.593, "premiums_fees_and_other_revenues": 14056000000 }, "comprehensive_income": { "comprehensive_income": -4161000000, "comprehensive_income_attributable_to_metlife_inc": -4164000000 }, "balance_sheet": { "total_investments": 471825000000, "cash_and_cash_equivalents": 19786000000, "separate_account_assets": 148960000000, "total_assets": 744608000000, "future_policy_benefits": 199120000000, "policyholder_account_balances": 250333000000, "short_term_debt": 289000000, "long_term_debt": 14301000000, "collateral_financing_arrangement": 254000000, "subordinated_debt_securities": 5145000000, "total_liabilities": 721894000000, "redeemable_noncontrolling_interests": 195000000, "accumulated_other_comprehensive_income_loss": -25304000000, "total_metlife_inc_stockholders_equity": 22226000000, "noncontrolling_interests": 293000000, "total_equity": 22519000000, "common_shares_outstanding": 631106615 }, "non_gaap_and_other_measures": { "adjusted_earnings_available_to_common_shareholders_per_diluted_common_share": 2.78, "adjusted_earnings_available_to_common_shareholders": 1780000000, "adjusted_earnings_available_to_common_by_segment": { "group_benefits": 523000000, "ris": 413000000, "asia": 602000000, "latin_america": 215000000, "emea": 108000000, "mim": 63000000, "corporate_and_other": -144000000 }, "book_value_per_common_share": 30.73, "adjusted_book_value_per_common_share": 59.41, "sources": "Adjusted earnings available to common shareholders and its segment split: MD&A of accession 0001099219-26-000062. Per-share adjusted earnings and book value per common share: Exhibit 99.1 to the Q3 2026 earnings release Form 8-K (accession 0001099219-26-000058)." } }, { "fiscal_year": 2025, "fiscal_quarter": 3, "label": "Q3 FY2025", "period_start": "2025-07-01", "period_end": "2025-09-30", "period_type": "three months", "source_accession": "0001099219-26-000062", "income_statement": { "premiums": 10555000000, "universal_life_and_investment_type_product_policy_fees": 1247000000, "net_investment_income": 6089000000, "other_revenues": 724000000, "net_investment_gains_losses": -325000000, "net_derivative_gains_losses": -929000000, "total_revenues": 17361000000, "policyholder_benefits_and_claims": 10369000000, "policyholder_liability_remeasurement_gains_losses": -159000000, "market_risk_benefit_remeasurement_gains_losses": -263000000, "interest_credited_to_policyholder_account_balances": 2561000000, "policyholder_dividends": 134000000, "other_expenses": 3509000000, "total_expenses": 16151000000, "income_before_provision_for_income_tax": 1210000000, "provision_for_income_tax": 308000000, "net_income": 902000000, "net_income_attributable_to_noncontrolling_interests": 6000000, "net_income_attributable_to_metlife_inc": 896000000, "preferred_stock_dividends": 66000000, "preferred_stock_redemption_premium": 12000000, "net_income_available_to_common_shareholders": 818000000, "basic_eps": 1.23, "diluted_eps": 1.22, "weighted_average_basic_shares": 664700000, "weighted_average_diluted_shares": 669100000, "dividends_declared_per_common_share": 0.568, "premiums_fees_and_other_revenues": 12526000000 }, "comprehensive_income": { "comprehensive_income": 3197000000, "comprehensive_income_attributable_to_metlife_inc": 3189000000 }, "non_gaap_and_other_measures": { "adjusted_earnings_available_to_common_shareholders_per_diluted_common_share": 2.37, "adjusted_earnings_available_to_common_shareholders": 1584000000, "adjusted_earnings_available_to_common_by_segment": { "group_benefits": 456000000, "ris": 441000000, "asia": 540000000, "latin_america": 148000000, "emea": 87000000, "mim": 58000000, "corporate_and_other": -146000000 }, "book_value_per_common_share": 39.52, "adjusted_book_value_per_common_share": 56.57, "sources": "Adjusted earnings available to common shareholders and its segment split: MD&A of accession 0001099219-26-000062. Per-share adjusted earnings and book value per common share: Exhibit 99.1 to the Q3 2026 earnings release Form 8-K (accession 0001099219-26-000058)." } } ], "year_to_date": { "label": "9M FY2026", "period_start": "2026-01-01", "period_end": "2026-09-30", "period_type": "nine months", "source_accession": "0001099219-26-000062", "prior_year_comparative": { "label": "9M FY2025", "period_start": "2025-01-01", "period_end": "2025-09-30", "period_type": "nine months", "source_accession": "0001099219-26-000062", "income_statement": { "premiums": 33088000000, "universal_life_and_investment_type_product_policy_fees": 3735000000, "net_investment_income": 16635000000, "other_revenues": 2090000000, "net_investment_gains_losses": -985000000, "net_derivative_gains_losses": -1293000000, "total_revenues": 53270000000, "policyholder_benefits_and_claims": 32942000000, "policyholder_liability_remeasurement_gains_losses": -185000000, "market_risk_benefit_remeasurement_gains_losses": -241000000, "interest_credited_to_policyholder_account_balances": 6608000000, "policyholder_dividends": 424000000, "other_expenses": 10178000000, "total_expenses": 49726000000, "income_before_provision_for_income_tax": 3544000000, "provision_for_income_tax": 957000000, "net_income": 2587000000, "net_income_attributable_to_noncontrolling_interests": 17000000, "net_income_attributable_to_metlife_inc": 2570000000, "preferred_stock_dividends": 163000000, "preferred_stock_redemption_premium": 12000000, "net_income_available_to_common_shareholders": 2395000000, "basic_eps": 3.56, "diluted_eps": 3.54, "weighted_average_basic_shares": 672500000, "weighted_average_diluted_shares": 677000000, "dividends_declared_per_common_share": 1.681 }, "comprehensive_income": { "comprehensive_income": 7282000000, "comprehensive_income_attributable_to_metlife_inc": 7264000000 }, "cash_flow": { "operating_cash_flow": 10016000000, "investing_cash_flow": -11321000000, "financing_cash_flow": 1161000000, "treasury_stock_acquired_share_repurchases": -2423000000, "preferred_dividends_paid": -163000000, "common_dividends_paid": -1134000000, "change_in_cash_and_cash_equivalents": 165000000 }, "non_gaap_and_other_measures": { "adjusted_earnings_available_to_common_shareholders_per_diluted_common_share": 6.34, "adjusted_earnings_available_to_common_shareholders": 4295000000, "adjusted_earnings_available_to_common_by_segment": { "group_benefits": 1227000000, "ris": 1217000000, "asia": 1258000000, "latin_america": 600000000, "emea": 270000000, "mim": 140000000, "corporate_and_other": -417000000 }, "sources": "Adjusted earnings available to common shareholders and its segment split: MD&A of accession 0001099219-26-000062. Per-share adjusted earnings and book value per common share: Exhibit 99.1 to the Q3 2026 earnings release Form 8-K (accession 0001099219-26-000058)." } }, "income_statement": { "premiums": 35373000000, "universal_life_and_investment_type_product_policy_fees": 4100000000, "net_investment_income": 18255000000, "other_revenues": 2550000000, "net_investment_gains_losses": -1528000000, "net_derivative_gains_losses": 0, "total_revenues": 58750000000, "policyholder_benefits_and_claims": 34673000000, "policyholder_liability_remeasurement_gains_losses": 143000000, "market_risk_benefit_remeasurement_gains_losses": -470000000, "interest_credited_to_policyholder_account_balances": 6942000000, "policyholder_dividends": 385000000, "other_expenses": 11535000000, "total_expenses": 53208000000, "income_before_provision_for_income_tax": 5542000000, "provision_for_income_tax": 1189000000, "net_income": 4353000000, "net_income_attributable_to_noncontrolling_interests": 35000000, "net_income_attributable_to_metlife_inc": 4318000000, "preferred_stock_dividends": 122000000, "preferred_stock_redemption_premium": 0, "net_income_available_to_common_shareholders": 4196000000, "basic_eps": 6.52, "diluted_eps": 6.48, "weighted_average_basic_shares": 643100000, "weighted_average_diluted_shares": 647500000, "dividends_declared_per_common_share": 1.753 }, "comprehensive_income": { "comprehensive_income": -2867000000, "comprehensive_income_attributable_to_metlife_inc": -2902000000 }, "cash_flow": { "operating_cash_flow": 6915000000, "investing_cash_flow": -17831000000, "financing_cash_flow": 8804000000, "treasury_stock_acquired_share_repurchases": -2128000000, "preferred_dividends_paid": -122000000, "common_dividends_paid": -1134000000, "change_in_cash_and_cash_equivalents": -2246000000 }, "non_gaap_and_other_measures": { "adjusted_earnings_available_to_common_shareholders_per_diluted_common_share": 7.63, "adjusted_earnings_available_to_common_shareholders": 4939000000, "adjusted_earnings_available_to_common_by_segment": { "group_benefits": 1465000000, "ris": 1241000000, "asia": 1509000000, "latin_america": 712000000, "emea": 326000000, "mim": 167000000, "corporate_and_other": -481000000 }, "sources": "Adjusted earnings available to common shareholders and its segment split: MD&A of accession 0001099219-26-000062. Per-share adjusted earnings and book value per common share: Exhibit 99.1 to the Q3 2026 earnings release Form 8-K (accession 0001099219-26-000058)." } }, "trailing_twelve_months": { "label": "TTM ended Q3 FY2026", "period_start": "2025-10-01", "period_end": "2026-09-30", "period_type": "trailing twelve months", "source_accession": "0001099219-26-000062", "derived_from": [ "0001099219-26-000013", "0001099219-26-000062" ], "derivation": "FY2025 (10-K) plus nine months ended September 30, 2026 less nine months ended September 30, 2025 (10-Q)", "income_statement": { "premiums": 52064000000, "universal_life_and_investment_type_product_policy_fees": 5368000000, "net_investment_income": 24179000000, "other_revenues": 3287000000, "total_revenues": 82564000000, "total_expenses": 75905000000, "income_before_provision_for_income_tax": 6659000000, "net_income": 5169000000, "net_income_available_to_common_shareholders": 4974000000 }, "cash_flow": { "operating_cash_flow": 13991000000 }, "non_gaap_and_other_measures": { "adjusted_earnings_available_to_common_shareholders": 6587000000, "sources": "Derived from MD&A figures in accessions 0001099219-26-000013 and 0001099219-26-000062." } }, "notes": [ "Schema: insurer. MetLife is a life insurer, annuity and employee-benefits provider and asset manager, so the record follows its own statement of operations (premiums, policy fees, net investment income, investment and derivative gains or losses, policyholder benefits, interest credited, other expenses) rather than a revenue / cost of goods / capital expenditure frame. Line items keep the same names in every period.", "Annual figures for FY2025, FY2024 and FY2023 are from the FY2025 Form 10-K (accession 0001099219-26-000013). The 10-K presents balance sheets only at December 31, 2025 and 2024, so FY2023 carries no balance sheet.", "Quarterly figures are the three months ended September 30, 2026 and September 30, 2025 from the Q3 2026 Form 10-Q (accession 0001099219-26-000062). The 10-Q presents cash flows only for the nine-month periods, so the quarters carry no cash flow statement; cash flows appear in the nine-month year-to-date block. The 10-Q presents balance sheets at September 30, 2026 and December 31, 2025 only, so Q3 FY2025 carries no balance sheet; the December 31, 2025 balance sheet is shown under FY2025 and is identical in both filings.", "Sign conventions follow the filings: 'net investment gains (losses)' and 'net derivative gains (losses)' are negative when losses; the remeasurement lines are expense lines captioned '(gains) losses', so a negative value there is a gain; cash outflows are negative. The 10-Q prints net derivative gains (losses) for the nine months ended September 30, 2026 as a dash, recorded here as zero.", "Net income here is consolidated net income (loss); diluted EPS is struck on net income available to MetLife, Inc.'s common shareholders, after noncontrolling interests, preferred stock dividends and, in 2025, a $12 million preferred stock redemption premium.", "Weighted average basic and diluted shares are from the earnings per common share notes (Note 23 of the 10-K, Note 17 of the 10-Q), printed in millions. Common shares outstanding are the period-end counts printed on the face of each balance sheet.", "Dividends declared per common share are from the statements of equity. The nine-month figures are the sum of the two amounts the 10-Q prints for each year (2026: $1.160 for the first six months plus $0.593 for the third quarter; 2025: $1.113 plus $0.568).", "Debt is shown as the four lines the balance sheet prints (short-term debt, long-term debt, collateral financing arrangement, subordinated debt securities); the company prints no single total-debt line, and none is derived here. The cash flow statement has no capital expenditure line, so no free cash flow figure is derived.", "Adjusted earnings available to common shareholders is MetLife's non-GAAP performance measure (also the measure its chief operating decision maker uses for segments). Totals and the segment split are from MD&A in the 10-K and 10-Q. Adjusted earnings per diluted common share, book value per common share and adjusted book value per common share are not printed in the 10-Q and are taken from Exhibit 99.1 of the Q3 2026 earnings release Form 8-K (accession 0001099219-26-000058).", "Segments: in the fourth quarter of 2025 MetLife reorganized its segments (MetLife Investment Management became a reportable segment; MetLife Holdings was removed and its business moved mainly to Corporate & Other). Consolidated figures were not affected. The 10-K states that the move of certain former MetLife Holdings products into Group Benefits and RIS was applied only to 2025, so the 10-K's FY2024 and FY2023 segment split is not fully comparable to FY2025; the 10-Q applies the reorganization to all periods it presents.", "Trailing twelve months ended September 30, 2026 is derived as FY2025 (10-K) plus the nine months ended September 30, 2026 less the nine months ended September 30, 2025 (10-Q). Per-share figures are not derived for this view.", "In Q3 2026 MetLife reported comprehensive loss of $4.16 billion despite net income of $2.41 billion: the statement of equity shows an other comprehensive loss of $6.56 billion for the quarter, and accumulated other comprehensive loss widened from $18.08 billion at December 31, 2025 to $25.30 billion at September 30, 2026, taking total MetLife, Inc. stockholders' equity from $28.40 billion to $22.23 billion.", "No stock splits in the periods covered; MetLife is a US domestic filer reporting in US dollars, so no currency conversion or ADS adjustment applies." ], "uncertainties": [ "Three-month cash flows for Q3 FY2026 and Q3 FY2025 are not shown: the Q3 10-Q prints cash flows for nine months only, and deriving the quarter would require the six-month cash flow statement from the Q2 10-Q, which is a different filing.", "The fourth quarter of 2025 is not shown as a quarter: neither filing prints it as a discrete three-month period.", "The Q3 2026 earnings release's expense-detail table prints 'Other expenses' of $3,965 million for Q3 2026 and $3,568 million for Q3 2025, while the 10-Q statement of operations prints $3,893 million and $3,509 million; total expenses agree ($17,522 million and $16,151 million). This record uses the statement of operations." ], "headline": { "period": "Q3 FY2026", "period_end_words": "September 30, 2026", "metrics": [ { "label": "Premiums, fees and other revenues", "format": "usd", "value": 14056000000, "text": "$14.06 billion", "exact": "$14,056,000,000", "compact": "$14.06B", "abs": "$14.06 billion", "prior_value": 12526000000, "prior": "$12.53 billion", "priorabs": "$12.53 billion", "yoy": "up 12.2%", "source": { "array": "quarterly", "field": "income_statement.premiums_fees_and_other_revenues", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001099219-26-000062", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001099219-26-000062", "gap_days": 365 } }, { "label": "Net income available to common shareholders", "format": "usd", "value": 2351000000, "text": "$2.35 billion", "exact": "$2,351,000,000", "compact": "$2.35B", "abs": "$2.35 billion", "prior_value": 818000000, "prior": "$818 million", "priorabs": "$818 million", "yoy": "up 187.4%", "source": { "array": "quarterly", "field": "income_statement.net_income_available_to_common_shareholders", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001099219-26-000062", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001099219-26-000062", "gap_days": 365 } }, { "label": "Diluted EPS", "format": "eps", "value": 3.67, "text": "$3.67", "exact": "$3.67", "compact": "$3.67", "abs": "$3.67", "prior_value": 1.22, "prior": "$1.22", "priorabs": "$1.22", "yoy": "up 200.8%", "source": { "array": "quarterly", "field": "income_statement.diluted_eps", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001099219-26-000062", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001099219-26-000062", "gap_days": 365 } }, { "label": "Adjusted earnings per diluted share", "format": "eps", "value": 2.78, "text": "$2.78", "exact": "$2.78", "compact": "$2.78", "abs": "$2.78", "prior_value": 2.37, "prior": "$2.37", "priorabs": "$2.37", "yoy": "up 17.3%", "source": { "array": "quarterly", "field": "non_gaap_and_other_measures.adjusted_earnings_available_to_common_shareholders_per_diluted_common_share", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001099219-26-000062", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001099219-26-000062", "gap_days": 365 } }, { "label": "Net derivative gains (losses)", "format": "usd", "value": 698000000, "text": "$698 million", "exact": "$698,000,000", "compact": "$698.00M", "abs": "$698 million", "prior_value": -929000000, "prior": "-$929 million", "priorabs": "$929 million", "yoy": "swung from -$929 million", "source": { "array": "quarterly", "field": "income_statement.net_derivative_gains_losses", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001099219-26-000062", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001099219-26-000062", "gap_days": 365 } } ], "summary": "MetLife reported net income available to common shareholders of $2.35 billion for Q3 FY2026, the quarter ended September 30, 2026, up 187.4% from $818 million a year earlier, or $3.67 per diluted share against $1.22. The increase came mainly from net derivative results, which swung to a gain of $698 million from a loss of $929 million. Adjusted earnings per diluted share, MetLife's non-GAAP measure that leaves out most investment and derivative gains and losses, were $2.78, up 17.3% from $2.37, and premiums, fees and other revenues were $14.06 billion, up 12.2%.", "qa": [ { "q": "How much did MetLife earn in Q3 FY2026?", "a": "MetLife reported net income available to common shareholders of $2.35 billion for Q3 FY2026, the quarter ended September 30, 2026, or $3.67 per diluted share. That is up 187.4% from $818 million, or $1.22 per diluted share, in the same quarter a year earlier." }, { "q": "Why did MetLife's net income rise in Q3 FY2026?", "a": "MetLife's net income rose in Q3 FY2026 mainly because net derivative results swung to a gain of $698 million from a loss of $929 million in the same quarter a year earlier. MetLife's adjusted earnings, which leave out most derivative gains and losses, grew far less, to $2.78 per diluted share from $2.37." }, { "q": "What was MetLife's adjusted EPS in Q3 FY2026?", "a": "MetLife's adjusted earnings available to common shareholders were $2.78 per diluted share in Q3 FY2026, the quarter ended September 30, 2026, up 17.3% from $2.37 a year earlier. Adjusted earnings is MetLife's non-GAAP measure and leaves out most investment and derivative gains and losses." }, { "q": "What was MetLife's revenue in Q3 FY2026?", "a": "MetLife reported premiums, fees and other revenues of $14.06 billion for Q3 FY2026, the quarter ended September 30, 2026, up 12.2% from $12.53 billion in the same quarter a year earlier. The measure combines premiums, policy fees and other revenues and leaves out net investment income and net investment and derivative gains and losses." } ] }, "company_details": { "Name": "Metlife Inc", "Ticker": "MET", "CIK": "0001099219", "Exchange": "NYSE", "State": "New York", "Incorporation": "Delaware", "SIC": "6311", "Office": "Finance", "Industry": "Life Insurance" }, "next_filing": { "predicted_date": "2027-02-18", "predicted_type": "10-K" }, "fiscal_period": { "fiscal_year": 2026, "fiscal_period": "Q3", "tag": "FY26Q3", "period_end": "2026-09-30", "form": "10-Q", "accession": "0001099219-26-000062", "fiscal_year_end": "1231", "source": "facts" }, "source_filings": [ { "role": "annual", "current": false, "form": "10-K", "fiscal_year": 2025, "fiscal_period": "FY", "tag": "FY25", "period_end": "2025-12-31", "filed": "2026-02-19", "accession": "0001099219-26-000013", "url": "https://www.sec.gov/Archives/edgar/data/1099219/000109921926000013/met-20251231.htm", "source": "reported" }, { "role": "quarterly", "current": true, "form": "10-Q", "fiscal_year": 2026, "fiscal_period": "Q3", "tag": "FY26Q3", "period_end": "2026-09-30", "filed": "2026-11-06", "accession": "0001099219-26-000062", "url": "https://www.sec.gov/Archives/edgar/data/1099219/000109921926000062/met-20260930.htm", "source": "facts" } ], "figure_sources": { "about": "Where each figure in this file is printed in its SEC filing. This block mirrors the paths of the figures: figure_sources.annual[0].income_statement.net_income is the source of annual[0].income_statement.net_income. Each entry reads '#', and the link is documents[] + '#': it opens the filing at the line that prints that number. A figure with no entry is not printed in a tagged filing, either because it was calculated (margins, free cash flow, trailing twelve months, a quarter derived by subtraction) or because it comes from an untagged earnings release.", "documents": { "d1": "https://www.sec.gov/Archives/edgar/data/1099219/000109921926000013/met-20251231.htm", "d2": "https://www.sec.gov/Archives/edgar/data/1099219/000109921926000062/met-20260930.htm" }, "annual": [ { "period_end": "2025-12-31", "income_statement": { "premiums": "d1#f-205", "universal_life_and_investment_type_product_policy_fees": "d1#f-208", "net_investment_income": "d1#f-211", "other_revenues": "d1#f-214", "net_investment_gains_losses": "d1#f-217", "net_derivative_gains_losses": "d1#f-220", "total_revenues": "d1#f-223", "policyholder_benefits_and_claims": "d1#f-226", "policyholder_liability_remeasurement_gains_losses": "d1#f-4343", "market_risk_benefit_remeasurement_gains_losses": "d1#f-232", "interest_credited_to_policyholder_account_balances": "d1#f-235", "policyholder_dividends": "d1#f-238", "other_expenses": "d1#f-241", "total_expenses": "d1#f-244", "income_before_provision_for_income_tax": "d1#f-280", "provision_for_income_tax": "d1#f-250", "net_income": "d1#f-277", "net_income_attributable_to_noncontrolling_interests": "d1#f-256", "net_income_attributable_to_metlife_inc": "d1#f-259", "preferred_stock_dividends": "d1#f-262", "preferred_stock_redemption_premium": "d1#f-404", "net_income_available_to_common_shareholders": "d1#f-268", "basic_eps": "d1#f-271", "diluted_eps": "d1#f-274", "weighted_average_basic_shares": "d1#f-9094", "weighted_average_diluted_shares": "d1#f-9100", "dividends_declared_per_common_share": "d1#f-415" }, "comprehensive_income": { "comprehensive_income": "d1#f-307", "comprehensive_income_attributable_to_metlife_inc": "d1#f-313" }, "cash_flow": { "operating_cash_flow": "d1#f-493", "investing_cash_flow": "d1#f-556", "financing_cash_flow": "d1#f-607", "treasury_stock_acquired_share_repurchases": "d1#f-589", "preferred_dividends_paid": "d1#f-414", "common_dividends_paid": "d1#f-601", "change_in_cash_and_cash_equivalents": "d1#f-613" }, "balance_sheet": { "total_investments": "d1#f-103", "cash_and_cash_equivalents": "d1#f-107", "separate_account_assets": "d1#f-127", "total_assets": "d1#f-129", "future_policy_benefits": "d1#f-131", "policyholder_account_balances": "d1#f-133", "short_term_debt": "d1#f-145", "long_term_debt": "d1#f-7438", "collateral_financing_arrangement": "d1#f-151", "subordinated_debt_securities": "d1#f-153", "total_liabilities": "d1#f-165", "redeemable_noncontrolling_interests": "d1#f-169", "accumulated_other_comprehensive_income_loss": "d1#f-195", "total_metlife_inc_stockholders_equity": "d1#f-197", "noncontrolling_interests": "d1#f-199", "total_equity": "d1#f-201", "common_shares_outstanding": "d1#f-183" }, "non_gaap_and_other_measures": { "adjusted_earnings_available_to_common_by_segment": { "group_benefits": "d1#f-787", "asia": "d1#f-789", "latin_america": "d1#f-790", "emea": "d1#f-791", "mim": "d1#f-7717", "corporate_and_other": "d1#f-1838" } } }, { "period_end": "2024-12-31", "income_statement": { "premiums": "d1#f-206", "universal_life_and_investment_type_product_policy_fees": "d1#f-209", "net_investment_income": "d1#f-212", "other_revenues": "d1#f-215", "net_investment_gains_losses": "d1#f-218", "net_derivative_gains_losses": "d1#f-221", "total_revenues": "d1#f-224", "policyholder_benefits_and_claims": "d1#f-227", "policyholder_liability_remeasurement_gains_losses": "d1#f-4344", "market_risk_benefit_remeasurement_gains_losses": "d1#f-233", "interest_credited_to_policyholder_account_balances": "d1#f-236", "policyholder_dividends": "d1#f-239", "other_expenses": "d1#f-242", "total_expenses": "d1#f-245", "income_before_provision_for_income_tax": "d1#f-248", "provision_for_income_tax": "d1#f-251", "net_income": "d1#f-254", "net_income_attributable_to_noncontrolling_interests": "d1#f-257", "net_income_attributable_to_metlife_inc": "d1#f-260", "preferred_stock_dividends": "d1#f-263", "net_income_available_to_common_shareholders": "d1#f-269", "basic_eps": "d1#f-272", "diluted_eps": "d1#f-275", "weighted_average_basic_shares": "d1#f-9095", "weighted_average_diluted_shares": "d1#f-9101", "dividends_declared_per_common_share": "d1#f-372" }, "comprehensive_income": { "comprehensive_income": "d1#f-308", "comprehensive_income_attributable_to_metlife_inc": "d1#f-314" }, "cash_flow": { "operating_cash_flow": "d1#f-494", "investing_cash_flow": "d1#f-557", "financing_cash_flow": "d1#f-608", "treasury_stock_acquired_share_repurchases": "d1#f-590", "preferred_dividends_paid": "d1#f-371", "common_dividends_paid": "d1#f-602", "change_in_cash_and_cash_equivalents": "d1#f-614" }, "balance_sheet": { "total_investments": "d1#f-104", "cash_and_cash_equivalents": "d1#f-108", "separate_account_assets": "d1#f-128", "total_assets": "d1#f-130", "future_policy_benefits": "d1#f-132", "policyholder_account_balances": "d1#f-134", "short_term_debt": "d1#f-146", "long_term_debt": "d1#f-7441", "collateral_financing_arrangement": "d1#f-152", "subordinated_debt_securities": "d1#f-154", "total_liabilities": "d1#f-166", "accumulated_other_comprehensive_income_loss": "d1#f-196", "total_metlife_inc_stockholders_equity": "d1#f-198", "noncontrolling_interests": "d1#f-200", "total_equity": "d1#f-202", "common_shares_outstanding": "d1#f-184" }, "non_gaap_and_other_measures": { "adjusted_earnings_available_to_common_by_segment": { "group_benefits": "d1#f-866", "ris": "d1#f-8946", "asia": "d1#f-4539", "latin_america": "d1#f-869", "emea": "d1#f-870", "mim": "d1#f-5568" } } }, { "period_end": "2023-12-31", "income_statement": { "premiums": "d1#f-207", "universal_life_and_investment_type_product_policy_fees": "d1#f-210", "net_investment_income": "d1#f-213", "other_revenues": "d1#f-216", "net_investment_gains_losses": "d1#f-219", "net_derivative_gains_losses": "d1#f-222", "total_revenues": "d1#f-225", "policyholder_benefits_and_claims": "d1#f-228", "policyholder_liability_remeasurement_gains_losses": "d1#f-4345", "market_risk_benefit_remeasurement_gains_losses": "d1#f-234", "interest_credited_to_policyholder_account_balances": "d1#f-237", "policyholder_dividends": "d1#f-240", "other_expenses": "d1#f-243", "total_expenses": "d1#f-246", "income_before_provision_for_income_tax": "d1#f-249", "provision_for_income_tax": "d1#f-252", "net_income": "d1#f-279", "net_income_attributable_to_noncontrolling_interests": "d1#f-258", "net_income_attributable_to_metlife_inc": "d1#f-261", "preferred_stock_dividends": "d1#f-264", "net_income_available_to_common_shareholders": "d1#f-270", "basic_eps": "d1#f-273", "diluted_eps": "d1#f-276", "weighted_average_basic_shares": "d1#f-9096", "weighted_average_diluted_shares": "d1#f-9102", "dividends_declared_per_common_share": "d1#f-335" }, "comprehensive_income": { "comprehensive_income": "d1#f-309", "comprehensive_income_attributable_to_metlife_inc": "d1#f-315" }, "cash_flow": { "operating_cash_flow": "d1#f-495", "investing_cash_flow": "d1#f-558", "financing_cash_flow": "d1#f-609", "treasury_stock_acquired_share_repurchases": "d1#f-591", "preferred_dividends_paid": "d1#f-334", "common_dividends_paid": "d1#f-603", "change_in_cash_and_cash_equivalents": "d1#f-615" }, "non_gaap_and_other_measures": { "adjusted_earnings_available_to_common_by_segment": { "group_benefits": "d1#f-944", "ris": "d1#f-945", "asia": "d1#f-946", "latin_america": "d1#f-947", "emea": "d1#f-948", "corporate_and_other": "d1#f-3432" } } } ], "quarterly": [ { "period_end": "2026-09-30", "income_statement": { "premiums": "d2#f-180", "universal_life_and_investment_type_product_policy_fees": "d2#f-184", "net_investment_income": "d2#f-188", "other_revenues": "d2#f-192", "net_investment_gains_losses": "d2#f-196", "net_derivative_gains_losses": "d2#f-200", "total_revenues": "d2#f-204", "policyholder_benefits_and_claims": "d2#f-208", "policyholder_liability_remeasurement_gains_losses": "d2#f-212", "market_risk_benefit_remeasurement_gains_losses": "d2#f-216", "interest_credited_to_policyholder_account_balances": "d2#f-220", "policyholder_dividends": "d2#f-224", "other_expenses": "d2#f-228", "total_expenses": "d2#f-232", "income_before_provision_for_income_tax": "d2#f-236", "provision_for_income_tax": "d2#f-240", "net_income": "d2#f-244", "net_income_attributable_to_noncontrolling_interests": "d2#f-248", "net_income_attributable_to_metlife_inc": "d2#f-252", "preferred_stock_dividends": "d2#f-256", "net_income_available_to_common_shareholders": "d2#f-264", "basic_eps": "d2#f-280", "diluted_eps": "d2#f-284", "weighted_average_basic_shares": "d2#f-6433", "weighted_average_diluted_shares": "d2#f-6441", "dividends_declared_per_common_share": "d2#f-341" }, "comprehensive_income": { "comprehensive_income": "d2#f-268", "comprehensive_income_attributable_to_metlife_inc": "d2#f-276" }, "balance_sheet": { "total_investments": "d2#f-77", "cash_and_cash_equivalents": "d2#f-81", "separate_account_assets": "d2#f-103", "total_assets": "d2#f-105", "future_policy_benefits": "d2#f-107", "policyholder_account_balances": "d2#f-109", "short_term_debt": "d2#f-121", "long_term_debt": "d2#f-125", "collateral_financing_arrangement": "d2#f-127", "subordinated_debt_securities": "d2#f-129", "total_liabilities": "d2#f-141", "redeemable_noncontrolling_interests": "d2#f-145", "accumulated_other_comprehensive_income_loss": "d2#f-170", "total_metlife_inc_stockholders_equity": "d2#f-172", "noncontrolling_interests": "d2#f-174", "total_equity": "d2#f-176", "common_shares_outstanding": "d2#f-158" }, "non_gaap_and_other_measures": { "adjusted_earnings_available_to_common_by_segment": { "group_benefits": "d2#f-631", "asia": "d2#f-633", "latin_america": "d2#f-634", "emea": "d2#f-635" } } }, { "period_end": "2025-09-30", "income_statement": { "premiums": "d2#f-181", "universal_life_and_investment_type_product_policy_fees": "d2#f-185", "net_investment_income": "d2#f-189", "other_revenues": "d2#f-193", "net_investment_gains_losses": "d2#f-197", "net_derivative_gains_losses": "d2#f-201", "total_revenues": "d2#f-205", "policyholder_benefits_and_claims": "d2#f-209", "policyholder_liability_remeasurement_gains_losses": "d2#f-213", "market_risk_benefit_remeasurement_gains_losses": "d2#f-217", "interest_credited_to_policyholder_account_balances": "d2#f-221", "policyholder_dividends": "d2#f-225", "other_expenses": "d2#f-229", "total_expenses": "d2#f-233", "income_before_provision_for_income_tax": "d2#f-237", "provision_for_income_tax": "d2#f-241", "net_income": "d2#f-245", "net_income_attributable_to_noncontrolling_interests": "d2#f-249", "net_income_attributable_to_metlife_inc": "d2#f-253", "preferred_stock_dividends": "d2#f-257", "preferred_stock_redemption_premium": "d2#f-261", "net_income_available_to_common_shareholders": "d2#f-265", "basic_eps": "d2#f-281", "diluted_eps": "d2#f-285", "weighted_average_basic_shares": "d2#f-6434", "weighted_average_diluted_shares": "d2#f-6442", "dividends_declared_per_common_share": "d2#f-427" }, "comprehensive_income": { "comprehensive_income": "d2#f-269", "comprehensive_income_attributable_to_metlife_inc": "d2#f-277" }, "non_gaap_and_other_measures": { "adjusted_earnings_available_to_common_by_segment": { "group_benefits": "d2#f-709", "ris": "d2#f-710", "asia": "d2#f-711", "latin_america": "d2#f-712", "emea": "d2#f-713", "corporate_and_other": "d2#f-3714" } } } ], "year_to_date": { "income_statement": { "premiums": "d2#f-182", "universal_life_and_investment_type_product_policy_fees": "d2#f-186", "net_investment_income": "d2#f-190", "other_revenues": "d2#f-194", "net_investment_gains_losses": "d2#f-198", "total_revenues": "d2#f-206", "policyholder_benefits_and_claims": "d2#f-210", "policyholder_liability_remeasurement_gains_losses": "d2#f-214", "market_risk_benefit_remeasurement_gains_losses": "d2#f-218", "interest_credited_to_policyholder_account_balances": "d2#f-222", "policyholder_dividends": "d2#f-226", "other_expenses": "d2#f-230", "total_expenses": "d2#f-234", "income_before_provision_for_income_tax": "d2#f-238", "provision_for_income_tax": "d2#f-242", "net_income": "d2#f-246", "net_income_attributable_to_noncontrolling_interests": "d2#f-250", "net_income_attributable_to_metlife_inc": "d2#f-254", "preferred_stock_dividends": "d2#f-258", "net_income_available_to_common_shareholders": "d2#f-266", "basic_eps": "d2#f-282", "diluted_eps": "d2#f-286", "weighted_average_basic_shares": "d2#f-6435", "weighted_average_diluted_shares": "d2#f-6443" }, "comprehensive_income": { "comprehensive_income": "d2#f-270", "comprehensive_income_attributable_to_metlife_inc": "d2#f-278" }, "cash_flow": { "operating_cash_flow": "d2#f-451", "investing_cash_flow": "d2#f-493", "financing_cash_flow": "d2#f-531", "treasury_stock_acquired_share_repurchases": "d2#f-519", "preferred_dividends_paid": "d2#f-258", "common_dividends_paid": "d2#f-527", "change_in_cash_and_cash_equivalents": "d2#f-535" }, "non_gaap_and_other_measures": { "adjusted_earnings_available_to_common_by_segment": { "group_benefits": "d2#f-787", "ris": "d2#f-788", "asia": "d2#f-789", "latin_america": "d2#f-790", "emea": "d2#f-791" } }, "prior_year_comparative": { "income_statement": { "premiums": "d2#f-183", "universal_life_and_investment_type_product_policy_fees": "d2#f-187", "net_investment_income": "d2#f-191", "other_revenues": "d2#f-195", "net_investment_gains_losses": "d2#f-199", "net_derivative_gains_losses": "d2#f-203", "total_revenues": "d2#f-207", "policyholder_benefits_and_claims": "d2#f-211", "policyholder_liability_remeasurement_gains_losses": "d2#f-215", "market_risk_benefit_remeasurement_gains_losses": "d2#f-219", "interest_credited_to_policyholder_account_balances": "d2#f-223", "policyholder_dividends": "d2#f-227", "other_expenses": "d2#f-231", "total_expenses": "d2#f-235", "income_before_provision_for_income_tax": "d2#f-239", "provision_for_income_tax": "d2#f-243", "net_income": "d2#f-247", "net_income_attributable_to_noncontrolling_interests": "d2#f-251", "net_income_attributable_to_metlife_inc": "d2#f-255", "preferred_stock_dividends": "d2#f-259", "preferred_stock_redemption_premium": "d2#f-263", "net_income_available_to_common_shareholders": "d2#f-267", "basic_eps": "d2#f-283", "diluted_eps": "d2#f-287", "weighted_average_basic_shares": "d2#f-6436", "weighted_average_diluted_shares": "d2#f-6444" }, "comprehensive_income": { "comprehensive_income": "d2#f-271", "comprehensive_income_attributable_to_metlife_inc": "d2#f-279" }, "cash_flow": { "operating_cash_flow": "d2#f-452", "investing_cash_flow": "d2#f-494", "financing_cash_flow": "d2#f-532", "treasury_stock_acquired_share_repurchases": "d2#f-520", "preferred_dividends_paid": "d2#f-259", "common_dividends_paid": "d2#f-528", "change_in_cash_and_cash_equivalents": "d2#f-536" }, "non_gaap_and_other_measures": { "adjusted_earnings_available_to_common_by_segment": { "group_benefits": "d2#f-865", "ris": "d2#f-866", "asia": "d2#f-867", "latin_america": "d2#f-868", "emea": "d2#f-869", "mim": "d2#f-870", "corporate_and_other": "d2#f-1966" } } } } } }